Beth C. Seidenberg - Feb 3, 2023 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
Feb 3, 2023
Transactions value $
$2,209,588
Form type
4
Date filed
2/9/2023, 03:36 PM
Previous filing
Oct 26, 2022
Next filing
Feb 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Purchase $334K +46.2K +3.44% $7.24 1.39M Feb 3, 2023 See footnote F1, F2, F3
transaction VERA Class A Common Stock Purchase $925K +132K +9.47% $7.03 1.52M Feb 6, 2023 See footnote F4, F5, F6
transaction VERA Class A Common Stock Purchase $623K +88K +5.78% $7.08 1.61M Feb 7, 2023 See footnote F7, F8, F9
transaction VERA Class A Common Stock Purchase $327K +45.4K +2.82% $7.22 1.65M Feb 8, 2023 See footnote F10, F11, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were purchased as follows: 44,635 by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 1,528 by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein.
F2 Represents weighted average purchase price. The shares were purchased at prices ranging from $7.21 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F3 Consists of 1,343,330 shares of Class A Common Stock held by KPCB XVI and 45,985 shares of Class A Common Stock held by XVI Founders.
F4 The shares were purchased as follows: 127,246 by KPCB XVI and 4,356 by XVI Founders.
F5 Represents weighted average purchase price. The shares were purchased at prices ranging from $6.86 to $7.24. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F6 Consists of 1,470,576 shares of Class A Common Stock held by KPCB XVI and 50,341 shares of Class A Common Stock held by XVI Founders.
F7 The shares were purchased as follows: 85,045 by KPCB XVI and 2,911 by XVI Founders.
F8 Represents weighted average purchase price. The shares were purchased at prices ranging from $6.97 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F9 Consists of 1,555,621 shares of Class A Common Stock held by KPCB XVI and 53,252 shares of Class A Common Stock held by XVI Founders.
F10 The shares were purchased as follows: 43,856 by KPCB XVI and 1,501 by XVI Founders.
F11 Represents weighted average purchase price. The shares were purchased at prices ranging from $7.06 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F12 Consists of 1,599,477 shares of Class A Common Stock held by KPCB XVI and 54,753 shares of Class A Common Stock held by XVI Founders.